Ulcerative colitis (UC) is characterized by erosion of the intestinal mucosal barrier, a pathology that can be exacerbated by microbial enzymatic activity, including bacterial sialidases that degrade mucin. Standard interventions such as broad-spectrum antibiotics may reduce pathogenic bacterial load but frequently disrupt microbial diversity and fail to restore mucosal thickness. The study reported here evaluated a sialidase inhibitor (SI) as a targeted microbiota-directed therapy intended to curb mucin degradation, preserve mucus, and promote mucosal healing while minimizing collateral disturbance to the gut microbial community.
The authors conducted a pilot randomized clinical trial in patients with mild-to-moderate UC. SI intervention was associated with statistically significant improvements in clinical symptoms and endoscopic outcomes relative to baseline or comparator groups as reported in the abstract. The clinical benefit observed in patients correlated with compositional and functional changes in the gut microbiome, notably an increase in taxa and metabolic pathways linked to production of short-chain fatty acids.
Clinical trial registration is reported as ChiCTR2000028767. The abstract does not present detailed trial metrics such as sample size, exact symptom or endoscopic scoring systems used, timepoints, or adverse event rates; those details were not reported in the source abstract and would need to be consulted in the full text for full appraisal.
Analysis of microbiome data from treated patients indicated enrichment of butyrate-producing taxa and beneficial metabolic pathways. Butyrate is a key microbial metabolite known to support colonic epithelial health and anti-inflammatory processes. The observed association between clinical improvement and enrichment of butyrate-related taxa supports a mechanistic link whereby SI-mediated modulation of sialidase activity may favor microbial functions that strengthen mucosal homeostasis.
In a dextran sulfate sodium (DSS)-induced colitis mouse model, SI treatment attenuated intestinal inflammation and restored the mucus layer. Restoration of mucosal integrity was accompanied by increased expression of mucin-related genes, specifically Muc2 and Tff3, which are central to mucus production and epithelial restitution. These preclinical findings align with the clinical observations and provide mechanistic support that reducing sialidase-driven mucin degradation can enhance barrier protection.
A key contrast reported in the study is between SI and broad-spectrum antibiotics. While antibiotics typically destabilize microbial diversity and community resilience, SI preserved microbial community structure and resilience. Importantly, SI selectively enriched beneficial mucolytic commensals, including Akkermansia muciniphila and Bacteroides acidifaciens, rather than causing a broad loss of taxa. This selective reshaping suggests SI acts by modulating specific enzymatic activity (sialidase) rather than by nonselective microbial killing.
The proposed mechanism centers on inhibition of bacterial sialidase activity that contributes to mucin degradation. By limiting sialidase-mediated mucin cleavage, SI appears to preserve the mucus layer and thereby reduce translocation of luminal antigens that drive inflammation. Upregulation of Muc2 and Tff3 in the murine model further indicates enhanced mucosal secretory function and epithelial repair, consistent with improved barrier resilience. The enrichment of butyrate-producing bacteria with SI may additionally support epithelial energy metabolism and anti-inflammatory signaling, reinforcing mucosal healing.
The combined clinical and preclinical evidence presented in the abstract positions SI as a promising microbiota-targeted therapeutic strategy for UC that aims to preserve the mucus barrier while selectively promoting beneficial microbial functions. Unlike antibiotics, SI may offer dual benefits: protection of mucosal thickness and restoration of a healthier microbial ecology, including enrichment of Akkermansia muciniphila and butyrate-producing taxa.
The abstract does not provide granular clinical trial data (such as exact endpoints, cohort sizes, duration, safety profile, or statistical values) or full methodological detail; these elements are likely available in the full publication. Further work would be needed to confirm durability, safety, optimal dosing, and mechanistic specifics in larger, controlled trials and to determine how SI integrates with existing UC therapies.
Conflict of interest: the authors declared no conflicts of interest in the source abstract. The study is registered as ChiCTR2000028767.